中文English
ISSN 1001-5256
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

药物性肝损伤治疗的进展与困惑

陈帅 杨长青

陈帅,杨长青. 药物性肝损伤治疗的进展与困惑[J]. 临床肝胆病杂志, 2021, 37(11): 2505-2509. DOI: 10.3969/j.issn.1001-5256.2021.11.001
引用本文: 陈帅,杨长青. 药物性肝损伤治疗的进展与困惑[J]. 临床肝胆病杂志, 2021, 37(11): 2505-2509. DOI: 10.3969/j.issn.1001-5256.2021.11.001
CHEN S, YANG CQ. Drug-induced liver injury: Advances and confusions in treatment [J]. J Clin Hepatol, 2021, 37(11): 2505-2509. DOI: 10.3969/j.issn.1001-5256.2021.11.001
Citation: CHEN S, YANG CQ. Drug-induced liver injury: Advances and confusions in treatment [J]. J Clin Hepatol, 2021, 37(11): 2505-2509. DOI: 10.3969/j.issn.1001-5256.2021.11.001

药物性肝损伤治疗的进展与困惑

DOI: 10.3969/j.issn.1001-5256.2021.11.001
基金项目: 

国家自然科学基金项目 81670571

国家自然科学基金项目 81820108006

上海市临床重点专科建设项目 SHSLCZDZK06801

上海申康三年行动计划重大临床研究项目 SHDC2020CR2030B

详细信息
    通讯作者:

    杨长青:cqyang@tongji.edu.cn

  • 中图分类号: R575

Drug-induced liver injury: Advances and confusions in treatment

Research funding: 

National Natural Science Foundation of China 81670571

National Natural Science Foundation of China 81820108006

Shanghai Clinical Key Specialty Project SHSLCZDZK06801

Clinical Research Plan of SHDC SHDC2020CR2030B

  • 摘要: 药物性肝损伤(DILI)是最常见、最严重的药物不良反应之一,严重者可引起急性肝衰竭甚至死亡。DILI发病机制尚未完全阐明,个体差异较显著,晚期DILI除肝移植外尚无有效的治疗方法,因此早期诊断、精准治疗显得尤为重要。现就近年来DILI治疗领域重要研究进展和难点问题进行述评。

     

  • [1] Drug-induced Liver Disease Study Group, Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the management of drug-induced liver injury[J]. J Clin Hepatol, 2015, 31(11): 1752-1769. DOI: 10.3969/j.issn.1001-5256.2015.11.002.

    中华医学会肝病学分会药物性肝病学组. 药物性肝损伤诊治指南[J]. 临床肝胆病杂志, 2015, 31(11): 1752-1769. DOI: 10.3969/j.issn.1001-5256.2015.11.002.
    [2] BJÖRNSSON ES, BERGMANN OM, BJÖRNSSON HK, et al. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland[J]. Gastroenterology, 2013, 144(7): 1419-1425, 1425. e1-3; quiz e19-20. DOI: 10.1053/j.gastro.2013.02.006.
    [3] BJÖRNSSON ES. Epidemiology and risk factors for idiosyncratic drug-induced liver injury[J]. Semin Liver Dis, 2014, 34(2): 115-122. DOI: 10.1055/s-0034-1375953.
    [4] SHEN T, LIU Y, SHANG J, et al. Incidence and etiology of drug-induced liver injury in mainland China[J]. Gastroenterology, 2019, 156(8): 2230-2241. e11. DOI: 10.1053/j.gastro.2019.02.002.
    [5] HUNT CM, PAPAY JI, STANULOVIC V, et al. Drug rechallenge following drug-induced liver injury[J]. Hepatology, 2017, 66(2): 646-654. DOI: 10.1002/hep.29152.
    [6] XU CF, JOHNSON T, WANG X, et al. HLA-B*57: 01 Confers Susceptibility to pazopanib-associated liver injury in patients with cancer[J]. Clin Cancer Res, 2016, 22(6): 1371-1377. DOI: 10.1158/1078-0432.CCR-15-2044.
    [7] WATKINS PB, LEWIS JH, KAPLOWITZ N, et al. Clinical pattern of tolvaptan-associated liver injury in subjects with autosomal dominant polycystic kidney disease: Analysis of clinical trials database[J]. Drug Saf, 2015, 38(11): 1103-1113. DOI: 10.1007/s40264-015-0327-3.
    [8] BANIASADI S, EFTEKHARI P, TABARSI P, et al. Protective effect of N-acetylcysteine on antituberculosis drug-induced hepatotoxicity[J]. Eur J Gastroenterol Hepatol, 2010, 22(10): 1235-1238. DOI: 10.1097/MEG.0b013e32833aa11b.
    [9] KNOWLES SR, SHAPIRO LE, SHEAR NH. Anticonvulsant hypersensitivity syndrome: Incidence, prevention and management[J]. Drug Saf, 1999, 21(6): 489-501. DOI: 10.2165/00002018-199921060-00005.
    [10] BORLAK J, van BÖMMEL F, BERG T. N-acetylcysteine and prednisolone treatment improved serum biochemistries in suspected flupirtine cases of severe idiosyncratic liver injury[J]. Liver Int, 2018, 38(2): 365-376. DOI: 10.1111/liv.13538.
    [11] KAN M, HIMES BE. Insights into glucocorticoid responses derived from omics studies[J]. Pharmacol Ther, 2021, 218: 107674. DOI: 10.1016/j.pharmthera.2020.107674.
    [12] DARNELL EP, MOORADIAN MJ, BARUCH EN, et al. Immune-related adverse events (irAEs): Diagnosis, management, and clinical pearls[J]. Curr Oncol Rep, 2020, 22(4): 39. DOI: 10.1007/s11912-020-0897-9.
    [13] NISHIDA N, KUDO M. Liver damage related to immune checkpoint inhibitors[J]. Hepatol Int, 2019, 13(3): 248-252. DOI: 10.1007/s12072-018-9921-7.
    [14] TUJIOS SR, LEE WM. Acute liver failure induced by idiosyncratic reaction to drugs: Challenges in diagnosis and therapy[J]. Liver Int, 2018, 38(1): 6-14. DOI: 10.1111/liv.13535.
    [15] WAN YM, WU JF, LI YH, et al. Prednisone is not beneficial for the treatment of severe drug-induced liver injury: An observational study (STROBE compliant)[J]. Medicine (Baltimore), 2019, 98(26): e15886. DOI: 10.1097/MD.0000000000015886.
    [16] MAO YM, ZENG MD, CHEN Y, Et al. Magnesium isoglycyrrhizinate in the treatment of chronic liver diseases: A randomized, double-blind, multi-doses, active drug controlled, multi-center study[J]. Chin J Hepatol, 2009, 17(11): 847-851. DOI: 10.3760/cma.j.issn.1007-3418.2009.11.013.

    茅益民, 曾民德, 陈勇, 等. 异甘草酸镁治疗ALT升高的慢性肝病的多中心、随机、双盲、多剂量、阳性药物平行对照临床研究[J]. 中华肝脏病杂志, 2009, 17(11): 847-851. DOI: 10.3760/cma.j.issn.1007-3418.2009.11.013.
    [17] WANG Y, WANG Z, GAO M, et al. Efficacy and safety of magnesium isoglycyrrhizinate injection in patients with acute drug-induced liver injury: A phase Ⅱ trial[J]. Liver Int, 2019, 39(11): 2102-2111. DOI: 10.1111/liv.14204.
    [18] ZHAO Z, BAO L, YU X, et al. Acute vanishing bile duct syndrome after therapy with cephalosporin, metronidazole, and clotrimazole: A case report[J]. Medicine (Baltimore), 2017, 96(36): e8009. DOI: 10.1097/MD.0000000000008009.
    [19] GU J, TANG SJ, TAN SY, et al. An open-label, randomized and multi-center clinical trial to evaluate the efficacy of Silibinin in preventing drug-induced liver injury[J]. Int J Clin Exp Med, 2015, 8(3): 4320-4327.
    [20] LUANGCHOSIRI C, THAKKINSTIAN A, CHITPHUK S, et al. A double-blinded randomized controlled trial of silymarin for the prevention of antituberculosis drug-induced liver injury[J]. BMC Complement Altern Med, 2015, 15: 334. DOI: 10.1186/s12906-015-0861-7.
    [21] ASGARSHIRAZI M, SHARIAT M, SHEIKH M. Comparison of efficacy of folic acid and silymarin in the management of antiepileptic drug induced liver injury: A randomized clinical trial[J]. Hepatobiliary Pancreat Dis Int, 2017, 16(3): 296-302. DOI: 10.1016/s1499-3872(16)60142-x.
    [22] DEVARBHAVI H, AITHAL G, TREEPRASERTSUK S, et al. Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines[J]. Hepatol Int, 2021, 15(2): 258-282. DOI: 10.1007/s12072-021-10144-3.
    [23] NAIQIONG W, LIANSHENG W, ZHANYING H, et al. A multicenter and randomized controlled trial of bicyclol in the treatment of statin-induced liver injury[J]. Med Sci Monit, 2017, 23: 5760-5766. DOI: 10.12659/msm.904090.
    [24] SALIBA F, CAMUS C, DURAND F, et al. Albumin dialysis with a noncell artificial liver support device in patients with acute liver failure: A randomized, controlled trial[J]. Ann Intern Med, 2013, 159(8): 522-531. DOI: 10.7326/0003-4819-159-8-201310150-00005.
    [25] LARSEN FS, SCHMIDT LE, BERNSMEIER C, et al. High-volume plasma exchange in patients with acute liver failure: An open randomised controlled trial[J]. J Hepatol, 2016, 64(1): 69-78. DOI: 10.1016/j.jhep.2015.08.018.
    [26] European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Drug-induced liver injury[J]. J Hepatol, 2019, 70(6): 1222-1261. DOI: 10.1016/j.jhep.2019.02.014.
    [27] HILLMAN L, GOTTFRIED M, WHITSETT M, et al. Clinical features and outcomes of complementary and alternative medicine induced acute liver failure and injury[J]. Am J Gastroenterol, 2016, 111(7): 958-965. DOI: 10.1038/ajg.2016.114.
    [28] ADAM R, KARAM V, CAILLIEZ V, et al. 2018 Annual Report of the European Liver Transplant Registry (ELTR) - 50-year evolution of liver transplantation[J]. Transpl Int, 2018, 31(12): 1293-1317. DOI: 10.1111/tri.13358.
    [29] WANG J, MA Z, NIU M, et al. Evidence chain-based causality identification in herb-induced liver injury: Exemplification of a well-known liver-restorative herb Polygonum multiflorum[J]. Front Med, 2015, 9(4): 457-467. DOI: 10.1007/s11684-015-0417-8.
    [30] ZHAO L, WANG Y, ZHANG Y. The potential diagnostic and therapeutic applications of exosomes in drug-induced liver injury[J]. Toxicol Lett, 2021, 337: 68-77. DOI: 10.1016/j.toxlet.2020.11.021.
    [31] MOMEN-HERAVI F, BALA S, BUKONG T, et al. Exosome-mediated delivery of functionally active miRNA-155 inhibitor to macrophages[J]. Nanomedicine, 2014, 10(7): 1517-1527. DOI: 10.1016/j.nano.2014.03.014.
    [32] POSSAMAI LA, MCPHAIL MJ, KHAMRI W, et al. The role of intestinal microbiota in murine models of acetaminophen-induced hepatotoxicity[J]. Liver Int, 2015, 35(3): 764-773. DOI: 10.1111/liv.12689.
  • 加载中
计量
  • 文章访问数:  300
  • HTML全文浏览量:  65
  • PDF下载量:  193
  • 被引次数: 0
出版历程
  • 收稿日期:  2021-08-30
  • 录用日期:  2021-08-30
  • 出版日期:  2021-11-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回